Amgen Q2 revenue tops $10B; IMDELLTRA + durvalumab advances
Amgen reported Q2 2026 revenue topping $10B, driven by six key drug groups. The update also cites Phase III progress for IMDELLTRA + durvalumab in ES—SCLC, a shorter infusion monitoring approach, an Opdivo biosimilar filing, and continued development including MariTide and a broad obesity Phase III program.
Amgen Inc. (NASDAQ:AMGN) reported Q2 2026 revenue above $10B, supported by six key drug groups. The company highlighted a Phase III IMDELLTRA and durvalumab win in ES—SCLC and said infusion monitoring was shorter. Amgen also filed for an Opdivo biosimilar while prioritizing R&D, and said MariTide and a broad obesity Phase III program are advancing.